Assess whether to resubmit, meet, or pause the program (aecb3f)

SITUATION The working file is disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled. RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT has to name To resubmit, meet, or Pause the program for this Pharma & Life Sciences Pharmacovigilance file.

DECISION RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose To resubmit, meet, / Pause the program using disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. RWE evidence-strategy director can defend To resubmit, meet, from disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled in a Pharma & Life Sciences challenge. 2. RWE evidence-strategy director cannot defend To resubmit, meet, from disproportionate reporting signal workbook; Pause the program is what the extract actually supports after an FAERS cluster in a demographic the trials under-enrolled. 3. An FAERS cluster in a demographic the trials under-enrolled never reached the population in disproportionate reporting signal workbook — reopen intake, do not close to resubmit, meet, or. 4. Two facts in disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled conflict for RWE evidence-strategy director; hold this Pharmacovigilance file.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 3. Check whether disproportionate reporting signal workbook supports the labeled claim RWE evidence-strategy director would keep. 4. For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move to resubmit, meet, or for RWE evidence-strategy director.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Pharmacovigilance packet (disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled). The follow-on Pharmacovigilance action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in disproportionate reporting signal workbook, then the action for RWE evidence-strategy director - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Pharmacovigilance finding in disproportionate reporting signal workbook that a second reviewer can re-perform - Missing page in disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled, if any